TITLE

Price and Prejudice

AUTHOR(S)
Bush, Laura
PUB. DATE
December 2005
SOURCE
BioPharm International;Dec2005, Vol. 18 Issue 12, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Editorial
ABSTRACT
The article presents the author's views on biasness in the field of biologics. It is reported that at a meeting of the American Association of Pharmaceutical Scientists, presenter Art Mlodozeniec claimed that if he brought up human growth hormone and said that the processes and impurities were easy to control, he was from the generic industry and supports approval for follow-on biologics. While, if he brought up the challenge of erythropoietin, he was from the innovator industry and opposed generics. According to the author, one sees all the facts and then select the ones that support a certain policy.
ACCESSION #
19667084

 

Related Articles

  • EU Biosimilar Debate Moves to Use in Clinical Practice. Moran, Nuala // BioWorld International;5/28/2008, Vol. 13 Issue 22, p1 

    The article looks at the debate concerning biosimilar products in the European market. Examples of arguments concerning biosimilar products include the process of approval and its use in clinical practice. Due to the fact that biosimilars are different from the originator product, issues of...

  • Sign of Things to Come? Houlton, Sarah // Pharmaceutical Executive;Feb2006, Vol. 26 Issue 2, p50 

    The article reports that the European Medicines Agency (EMEA) intends to complete its guidelines for the approval of generic copies of biologic medicines in early 2006. The approval of biogenerics could be a potential business opportunity for generic companies. The initial guidelines are...

  • Generic Biologics? Not Yet. Sellers, L.J. // Pharmaceutical Executive;Oct2003, Vol. 23 Issue 10, p18 

    Reports on the statement by Martin Harvey Allchurch, spokesperson for the European Agency for the Evaluation of Medicinal Products, that the story in the "New York Times" about Omnitrop somatropin biogeneric is not true. Comments on Novartis/Sandoz' application for the marketing of Omnitrop i...

  • Pharma swept up in biogenerics gold rush. Ratner, Mark // Nature Biotechnology;Apr2009, Vol. 27 Issue 4, p299 

    This article discusses the involvement of large pharmaceutical companies in the burgeoning field of biogenerics. Numerous drug corporations such as Merck BioVentures (MBV) and Pfizer have put up money to either bolster or acquire biotechnology companies such as Insmed and Wyeth. Biogenerics...

  • Generic makers are seeing promise in field of biotech engineering. Kirsche, Michelle L. // Drug Store News;2/16/2004, Vol. 26 Issue 2, p46 

    Reports that generic drug makers in the U.S. are seeing promise in the field of generic biologics. Scientific and economic debate over generic biologics; Efforts to create a scientific and regulatory framework for generic biologics; Predicted strong performance n the sector again in 2004;...

  • The Global Map of Biosimilars in 2014. Galbraith, Daniel // Pharmaceutical Processing;Apr2014, Vol. 29 Issue 4, p12 

    The article discusses the importance placed among pharmaceutical companies on biologics. Noted are the disadvantages of biologic drugs such as the length of time and the cost associated to development and production while indicated is one benefit, which is the protection among manufacturers on...

  • Molecule of the Month. Bolinger, Julie D.; Lindsley, Craig W. // Current Topics in Medicinal Chemistry;Aug2007, Vol. 7 Issue 16, p1643 

    The most prescribed and top selling drugs of 2006: generics, biologics and, of course, Lipitor�. In the spring of 2007, data for the top 200 prescription drugs, in terms of both sales and number of dispensed prescriptions, was released [1-3]. Total sales of prescription drugs reached $275...

  • The importance of Characterisation in Biosimilars Development. Siew, Adeline // Pharmaceutical Technology Europe;Sep2013, Vol. 25 Issue 9, p32 

    The article presents views of several pharmaceutical industry experts discussing the requirements and challenges involved in the manufacturing and development of the biosimilar products. It informs that biosimilar products and generic drugs are prepared from living cells and active...

  • Keeping Pace. Gray, Nicole // European Pharmaceutical Executive;Jul/Aug2006, p38 

    The article provides information on the developments related to pharmaceutical companies in 2005. There were 17 new products out in the market, the number of consolidations increased, and biologics grew faster than the overall market. In addition, generic prescriptions increased by 13% and $17...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics